Effects of 10alpha,25-dihydroxyvitamin D3 on doxorubicin-induced chromosomal aberrations in rat bone marrow cells.
The present study was carried out to evaluate the effects of 1alpha,25-dihydroxyvitamin D3 (VD) on chromosomal aberrations induced by doxorubicin (DXR). Wistar rats were divided into eight experimental groups of five animals each. Control group animals were treated with i.p. distilled water. The animals in three VD groups were given only VD for 4, 6 or 8 weeks. In the DXR groups the animals were given only DXR. In the combination groups VD doses were given for 4, 6 or 8 weeks for each group and DXR was injected 24 h before sacrificing the rats. DXR (50 mg/100 g b.w.) was injected intraperitoneally and VD by gavage 3 microg/kg/day twice weekly. Animals treated with both VD and DXR showed a low frequency of chromosomal aberrations and abnormal metaphases when compared with animals treated with DXR alone (p < 0.0001). The numbers of both chromosomal aberrations and abnormal metaphases were similar in weeks 6 and 8 (p > 0.05) and lower than those in week 4 for the VD groups (p < 0.0001). Under the present experimental conditions, the efficiency of VD in protecting cells against DXR-induced chromosome damage was found to be dose dependent. The protective effects of VD on chromosome aberrations induced by DXR are discussed in the light of literature data.
Kocak
Nilufer
N
Department of Internal Medicine, Kocaeli University, Medical School, Derince-Kocaeli, Turkey.
Ustün
Hasan
H
Gülkaç
Mehmet Doğan
MD
Kanli
Aylin Ozön
AO
Borazan
Ali
A
Yilmaz
Ahmet
A
D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects*; D002117:Calcitriol / Q000008:administration & dosage / Q000494:pharmacology*; D002869:Chromosome Aberrations / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D008677:Metaphase / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar
D004317:Doxorubicin; D002117:Calcitriol